Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The leading professional organisation for medical oncology
Browse the scientific and educational sessions and more!
View all accepted abstracts here.
Submit your questions to the experts and get best practice recommendations for improved patient care in this real-time discussion.
Share your research at the best platform for immuno-oncology
Submit your abstract to TAT 2022, the “Home of Phase I in Oncology”, Onsite and Online on 7-9 March 2022!
Online application is open until 28 September 2021
Last chance to apply! Submit your application by 29 September 2021
On the ESMO Perspectives, Dario Trapani reflects on sustainability in cancer care
Findings from the IMCgp100-202 study
Data from early clinical trials presented at the ESMO Congress 2021 suggest that new anticancer treatments are on the horizon, with a clear emphasis on precision medicine.
Findings from the Vax-On study show a favourable safety profile of mRNA-based COVID-19 vaccine in patients with solid tumours during active anticancer treatment
Evidence for efficacy is based on the results from the innovaTV 204 study
Findings from the PANAMA study (AIO KRK 0212)
Findings from international registries improve knowledge on how to manage cancer care in the pandemic era
Initial delays to antibody production are followed by similar levels of vaccine efficacy after a second vaccine dose
Findings from the COSMIC-021 study
Findings from the third ESMO Resilience Task Force survey highlight the detrimental effect of long working hours and changes to clinical routine on future career plans
Findings from international registries improve knowledge on how to manage cancer care in the pandemic era
Initial delays to antibody production are followed by similar levels of vaccine efficacy after a second vaccine dose
Findings from the third ESMO Resilience Task Force survey highlight the detrimental effect of long working hours and changes to clinical routine on future career plans
Practice-changing results were also presented in bronchopulmonary and non-pancreatic NETs with somatostatin analogues and VEGFR inhibitors
Latest findings on the use of single-agent and combination immunotherapy are not conclusive, despite being promising
Projections by the European Commission – Joint Research Centre from Ispra, Italy, estimate a 21.4% increase in cancer cases in 20 years’ time
Malignant pleural mesothelioma is a rare and fatal disease with very little improvement in survival in recent years, mirroring very limited therapeutic advances. After a long-awaited time, improvement in patient survival was achieved with the introduction of nivolumab plus ipilimumab in the first-line setting, as demonstrated in the CheckMate 743 trial.
Findings from several studies highlight the increasing utility of this approach to identify druggable genetic alterations
Most, but not all, patients on chemotherapy or immunotherapy for solid tumours had an adequate immune response after two doses of mRNA-1273 vaccination, with no new safety concerns
Findings from the IMCgp100-202 study
Findings from the Vax-On study show a favourable safety profile of mRNA-based COVID-19 vaccine in patients with solid tumours during active anticancer treatment
Evidence for efficacy is based on the results from the innovaTV 204 study
Findings from the PANAMA study (AIO KRK 0212)
Findings from the COSMIC-021 study
Findings from a population-based cohort study
The results of the KEYNOTE-122 study
Critical role of government-sponsored cancer research
Findings from samples of the AIO ColoPredictPlus 2.0 registry study
Data from early clinical trials presented at the ESMO Congress 2021 suggest that new anticancer treatments are on the horizon, with a clear emphasis on precision medicine.
First concrete results presented at the ESMO Congress 2021 confirm need to promote vaccination in patients with cancer
FIRSTMAPPP, the first randomised study in malignant pheochromocytoma and paraganglioma (MPP) has found that sunitinib prolongs progression-free survival (PFS) by more than five months
The PEACE-1 and STAMPEDE studies found that the addition of abiraterone acetate plus prednisolone (AAP) to standard therapy lengthened survival compared to standard therapy alone.
Adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with hormone receptor (HR) positive, HER2 negative advanced breast cancer, according to late breaking results of the MONALEESA-2 trial
The addition of immunotherapy to standard first-line treatment extends survival by eight months
The first randomised phase III clinical trial in stage II melanoma has shows a 35% reduction in the risk of recurrence with adjuvant pembrolizumab compared with placebo
Study shows that a significant proportion of survivors continue to suffer from burdensome symptoms for several years
Two studies [to be] presented at the ESMO Congress 2021 suggest a need for broader education on current standards of cancer care
ESMO has announced today the winners of the 2021 Society Awards.
Record Impact Factor increases for ESMO journals
ESMO Congress 2021: an enhanced virtual experience
Timely presentations of trial data will accelerate transition from research to practice
ESMO is pleased to offer members the opportunity to make a more active contribution to the development of the Society as we are looking to fill an important editorial position in one of our journals and for membership of two of our Working Groups.
Decide is the Health Decision Hub hosted by the World Health Organisation
ESMO has announced a collaboration with the WHO’s International Agency for Research on Cancer (IARC) to support them in the development of an online learning platform which integrates all research for cancer prevention in one easy-to-access point.
ESMO has taken the decision due to the uncertain evolution of the Coronavirus pandemic in the Asia-Pacific region and to avoid any risks to the health of the Faculty, delegates and staff.
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
Resources such as abstracts, presentations and webcasts from meetings can be accessed by ESMO members and conference delegates throughout all the year
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Switzerland
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
Take the CME test with E-learning and V-learning modules
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
